Advertise on podcast: Conversations Life Science Leaders Aren't Having

Welcome back to Conversations Life Science Leaders Aren’t Having. In this episode, we sit down with Jason Matuszewski, CEO of BioStem Technologies, a regenerative medicine company based in South Florida focused on advanced wound care solutions using placental tissue. From the outset, what stands out most about Jason is his authenticity—he leads without pretense and brings a genuine passion for patients, his team, and the broader mission of BioStem. In our conversation, Jason takes us through the winding journey of BioStem’s evolution—from its roots in medical tourism treating high-net-worth individuals and professional athletes, to its current focus on serving underserved patient populations dealing with chronic wounds. He shares how the company pivoted in 2018, riding the waves of the COVID-19 pandemic and using that time to innovate and develop a proprietary processing technology called BioRetain. Reflecting on more than a decade of leadership, Jason opens up about who he’s become in the process—an evolving public company CEO who has learned to lead through uncertainty and build an empowering, family-oriented culture he refers to as “The Stem.” He shares how mentorship, humility, and a flat organizational structure have helped shape a culture where every team member—from lab to accounting—feels connected to the patient impact of their work. A unique part of this culture includes a weekly “Opening Bell” meeting, where Jason highlights real patient stories to keep the mission front and center. Jason doesn’t shy away from tough industry topics either. He challenges his peers in the life sciences—particularly in wound care—to engage in more collaborative conversations around coverage, payment, and innovation. He points out that fragmentation in the industry has stalled progress and hurt patients, and he’s committed to being "an adult in the room" to drive change, influence policy, and reduce systemic inefficiencies that delay product delivery to those who need them most. As BioStem looks ahead, Jason envisions expanding the product portfolio, continuing to advocate for patients at both commercial and government levels, and solidifying South Florida as a hub for medtech innovation. He closes with a heartfelt reminder of why this work matters—every wound healed, every limb saved, is a life impacted—and that is what keeps him and his team energized each day. To learn more about BioStem and follow Jason’s journey, visit biostemtech.com or connect with him on LinkedIn. Stay tuned for more powerful conversations just like this one.

In this episode of *Conversations Life Science Leaders Aren't Having*, host Jeff Harmon sits down with Arun Swaminathan, CEO of Coya Therapeutics, for a deep dive into leadership, innovation, and the mission to transform patient lives. Arun shares his journey from scientist to CEO, reflecting on the pivotal moments that shifted his perspective from career growth to a passion for turning science into real-world impact. He recounts the profound influence of working alongside pioneers in transplant immunology and the leap of faith that led him to co-found a biotech company a decade ago. Now leading Coya, Arun is focused on advancing therapies for ALS and other neurodegenerative diseases, with a vision of improving patient outcomes and quality of life. The conversation explores the evolving role of curiosity in leadership—how Arun continues to foster a learning mindset beyond the lab and into the boardroom. He discusses the critical balance of maintaining passion while implementing operational excellence, ensuring that bold ideas translate into actionable success. A particularly insightful segment revolves around company culture and leadership write transition. Arun reflects on taking the reins from founding CEO Howard Berman, whose personal connection to ALS shaped the company’s mission. While bringing his own leadership style, Arun emphasizes the importance of maintaining the organization’s DNA—keeping the patient at the center of every decision. He candidly shares how Coya fosters psychological safety within its team, encouraging cross-functional problem-solving and idea-sharing across traditional silos. Jeff and Arun also tackle a broader challenge in the biotech industry—the need for increased collaboration among competitors. Arun advocates for more open dialogue between leaders to address shared barriers, from patient recruitment to regulatory pathways, while still maintaining competitive innovation. He challenges himself and his peers to dedicate time to industry-wide problem-solving, likening it to building a better highway for all companies while each focuses on perfecting their individual vehicles. As the discussion winds down, Arun outlines Coya’s ambitious plans for 2025, including advancing its Phase 2B clinical trial for ALS and exploring new applications for its therapies in neurodegenerative diseases. His dream? To see Coya’s work lead to a future where ALS patients can maintain their quality of life, a goal that fuels every aspect of his leadership. This episode is a must-listen for biotech professionals, leaders navigating cultural shifts, and anyone passionate about the intersection of science and impact. Follow Coya Therapeutics on their website, LinkedIn, and social media to stay updated on their groundbreaking work. Links mentioned: - Coya Therapeutics Website: https://coyatherapeutics.com/ - LinkedIn: https://www.linkedin.com/company/coya-therapeutics/ - Twitter/X: https://twitter.com/CoyaTx - YouTube: https://www.youtube.com/channel/UCTG29yxsbR7vcA8ZAMNPi4Q Tune in and be inspired by Arun’s leadership philosophy and the powerful mission driving Coya forward!

In this episode, Jeff sits down with Dr. Hernan Bazan, a vascular surgeon, biotech entrepreneur, and CEO of South Rampart Pharma, to explore a groundbreaking approach to pain management and drug development. Dr. Bazan shares his journey from the operating room to leading a life sciences company, discussing the unique approach his team has taken to develop SRP-001, a novel, non-opioid pain treatment that has received FDA fast-track designation. Throughout the conversation, Dr. Bazan highlights how his dual perspective as a practicing physician and a biotech leader allows him to challenge the traditional drug development model. He dives into the importance of capital efficiency, leveraging NIH funding, and assembling a world-class team without the typical overhead of a life sciences company. He also reflects on his leadership philosophy, emphasizing that leadership is relationships and that true execution requires understanding every aspect of the business—not just delegating. Jeff and Dr. Bazan discuss the broader landscape of pain management, the growing investor and regulatory interest in alternatives to opioids, and what it takes for clinicians with innovative ideas to turn them into reality. The episode is a must-listen for anyone in the life sciences space looking to rethink execution, funding, and leadership in biotech. Key Takeaways: 🔹 How Dr. Bazan transitioned from vascular surgery to biotech innovation 🔹 The unique, capital-efficient model South Rampart Pharma is using to develop new drugs 🔹 Why having a practicing physician’s perspective is valuable in biotech 🔹 The importance of relationships in leadership and execution 🔹 The growing momentum in the pain management space and what it means for investors 🔹 Advice for clinicians and scientists looking to bring new medical innovations to market Resources & Links: 🔗 Learn more about South Rampart Pharma: www.southrampartpharma.com 🔗 Follow South Rampart Pharma on LinkedIn - https://www.linkedin.com/company/south-rampart-pharma-llc/ 🔗 Read the latest coverage in BioSpace - https://www.biospace.com/drug-development/vertexs-journavx-changes-the-pain-treatment-landscape-but-opioids-here-to-stay Dr. Bazan’s insights provide a mini-masterclass in executing innovation in biotech. If you're an entrepreneur, investor, or clinician with an idea, this episode will challenge you to think differently about leadership, funding, and bringing novel treatments to patients.

In this episode of Conversations Life Science Leaders Aren't Having, Jeff Harmon welcomes leadership advisor and coach Tony Martignetti for an insightful discussion about connection, mentorship, and leadership transformation in the life sciences industry. Tony, the founder of Inspired Purpose Partners, has dedicated his career to guiding highly technical professionals—what he calls “outlier leaders”—who have the potential to make a massive impact but often struggle with communication and connection. Having spent years in life sciences as a finance and strategy leader, Tony understands the challenges of translating technical expertise into leadership that inspires and influences. He shares his personal journey of breaking free from an analytical-only identity to embrace his true strengths—helping others uncover their brilliance and bring it forward. Throughout the conversation, Jeff and Tony explore the importance of mentorship, the power of vulnerability in leadership, and the necessity of breaking down silos in biotech and pharma. Tony shares real-life experiences of when diverse perspectives led to better decision-making—and when the lack of them led to failure. They discuss how leaders can create safe spaces for meaningful conversations and the essential role of self-awareness in professional growth. Tony also introduces his program, Campfires of Connection, designed to deepen relationships within organizations and drive innovation through stronger human connection. He offers thought-provoking questions for senior life science leaders, challenging them to redefine success, think beyond traditional industry borders, and ask, Who else should we be talking to? Join Jeff and Tony for a conversation that will change the way you think about leadership, connection, and the future of innovation in life sciences. Key Takeaways: Why connection is critical for technical leaders looking to inspire and influence The role of mentorship and how leaders can foster meaningful, open conversations How breaking down silos and engaging diverse perspectives leads to better outcomes The balance between hard technical expertise and “soft skills” that drive real results Why life science leaders must redefine success to balance innovation with humanity Resources & Links: 🔗 Connect with Tony on LinkedIn: Tony Martignetti 🔗 Learn more about Inspired Purpose Partners: iPurposePartners.com 🔗 Explore Campfires of Connection: https://www.ipurposepartners.com/campfiresofconnection Support the Show: If you enjoyed this episode, please take a moment to share it with a colleague or leave a review. Your support helps bring more unspoken conversations to the forefront of life science leadership. 🎧 Listen, reflect, and keep the conversation going!

Welcome to Conversations Life Science Leaders Aren’t Having, hosted by Jeff Harmon. In this insightful episode, Jeff sits down with Mehmet Baha, a world-renowned coach, teacher, and consultant specializing in psychological safety and fostering deeply human, high-performing workplace cultures. Based in Berlin and originally from Cyprus, Baha brings a unique perspective shaped by years of global experience, including his time as one of Facebook's first European employees and as a Fulbright Scholar. Baha’s approach combines compassion with actionable strategies, demonstrating that humanity and high performance are not mutually exclusive. In this episode, Baha shares his personal journey, which led him to champion psychological safety, drawing from both challenging and empowering experiences in his career. He reveals how environments with high psychological safety foster innovation and collaboration, while fear-based cultures can lead to burnout and disengagement. The conversation dives into key trends shaping workplaces in 2025, including employee well-being, diversity, equity, and inclusion (DEI), and the role of artificial intelligence (AI) in preserving our humanity at work. Baha emphasizes that leaders must focus on building trust, fostering curiosity, and creating positive momentum by engaging "movers" within their organizations to drive meaningful cultural shifts. Listeners will also hear Baha’s practical advice on managing resistance to change, fostering collaboration, and ensuring psychological safety during turbulent times. He highlights real-world examples, such as the contrasting approaches of two companies to layoffs, to illustrate the importance of leading with empathy and clarity. As a father, musician, and lifelong learner, Baha offers personal insights into how curiosity, mindfulness, and prioritization shape his leadership philosophy. He leaves leaders with a powerful question to carry into the year: “How can we be humane, show compassion, and simultaneously achieve high performance?” Baha’s latest book, Creating Psychological Safety at Work, is a treasure trove of practical tools, inspiring stories, and thought-provoking questions to help leaders cultivate safer, more inclusive workplaces. Links and Resources: Baha’s book: Creating Psychological Safety at Work - https://a.co/d/0jV0sjB McKinsey Report on DEI and financial performance - https://www.mckinsey.com/featured-insights/diversity-and-inclusion/diversity-matters-even-more-the-case-for-holistic-impact Connect with Baha on LinkedIn - https://www.linkedin.com/in/mbaha/

In this insightful episode, Jeff Harmon sits down with David Schull, a partner at Russo Partners, for an in-depth conversation about leadership, life science communications, and staying passionate in a challenging industry. David shares the remarkable journey of Russo Partners, a boutique firm specializing in corporate communications for emerging healthcare companies. With over 30 years of experience, David explains how his team, composed of scientists, physicians, and industry veterans, uniquely supports biopharma, medtech, and healthcare services in shaping their stories for investors and strategic partners. David reflects on his early days in the field and the lessons he’s learned along the way—highlighting the importance of curiosity, a commitment to continuous learning, and building strong relationships. He emphasizes the core values that drive Russo Partners, including client focus, trust, forward thinking, and most notably, passion. Passion, he believes, is key to thriving in life sciences, an industry where innovation can truly change lives. Throughout the conversation, David and Jeff dive into some of the crucial but often neglected conversations that life science leaders need to have. David discusses the importance of knowing when to pivot or even stop a project, a reality check that too few executives are willing to face. As they look ahead to 2025, David highlights key trends, such as the continued focus on obesity treatment, advances in immuno-oncology, and the evolving role of artificial intelligence in drug development. He also underscores the critical need for scientific entrepreneurs to develop strong business acumen. To close the episode, David offers a thought-provoking challenge. If you’re looking for inspiration and actionable insights into leadership and communication in the life sciences industry, this episode is a must-listen. For more information on David Schull and Russo Partners, visit www.russopartnersllc.com or connect with David on LinkedIn - https://www.linkedin.com/in/davidschull/

In this episode of Conversations Life Science Leaders Aren't Having, Jeff Harmon sits down with Manijeh Goldberg, founder and CEO of Privo Technologies. Privo is an innovative biotechnology company pioneering nanotechnology-based therapies designed to tackle cancer more effectively, reduce recurrence, and minimize the debilitating side effects of traditional treatments like chemotherapy and radiation. Manijeh shares the inspiring journey that brought her from a career in medical devices to leading a groundbreaking biotech firm. Throughout their conversation, Manijeh delves into the challenges and rewards of running a biotech company, emphasizing the resilience and perseverance required to navigate this complex field. She reflects on her own pivot from engineering to nanotechnology and her decision to pursue advanced degrees later in life, demonstrating that it’s never too late to chase new dreams or make a profound impact. Manijeh's passion for innovation shines as she describes Privo's current clinical trials, which focus on a novel nano-engineered patch for treating head and neck cancers. The patch delivers highly potent chemotherapeutic agents directly to tumors, reducing systemic toxicity and improving patients’ quality of life. She also highlights an exciting extension of their work into veterinary oncology, where similar treatments are showing promise in companion animals like dogs, cats, and even penguins. This conversation offers invaluable insights into leadership, resilience, and the drive to create meaningful change. Manijeh also challenges the status quo in drug development, urging investors and leaders to look beyond traditional molds and recognize the transformative potential of innovative solutions. If you're inspired by stories of passion, perseverance, and innovation, you won’t want to miss this episode. Learn more about Privo Technologies at www.PrivoTechnologies.com, where you can explore their pioneering work in oncology for both humans and animals. Thank you for tuning in! If you enjoyed this episode, please share it with a colleague or leave a review to support the show. Until next time, take care and keep going.

In this episode of Conversations Life Science Leaders Aren't Having, Jeff Harmon sits down with keynote speaker and consultant Michael Neese, who is passionate about transforming organizations through kindness-centered leadership. Michael brings a wealth of experience from his 18 years in life sciences, particularly in clinical trials and drug development, and has recently shifted his focus to helping leaders and teams build more human-centered, compassionate workplaces. In their conversation, Michael shares his vision of a future where kindness is the driving force behind innovation and productivity, a future where "people are valued, and all voices are heard." Throughout the episode, Michael discusses his journey across five different industries and how a defining moment of reflection led him to realize that the key to success in both life and leadership is treating others with kindness. His latest book, In Kind, encapsulates this philosophy. He reflects on the times when staying true to his values, even in the face of difficult situations, has made all the difference, noting that "when I've been attentive to my colleagues and supervisors, everything has gone better." Michael offers insights on how life science leaders—and anyone in a corporate environment—can focus on supporting their teams through kindness and psychological safety, helping to foster an environment where people can thrive. He points out that the technical aspects of work are important, but true leadership lies in how we treat one another. As Michael notes, "if we’re not here for each other, then what’s the point?" Michael highlights that kindness is not just a "warm fuzzy" concept—it’s a powerful leadership tool that can transform teams and organizations. His parting wisdom? "Be courageous. Stand up for kindness, even when it’s hard." It’s a message that resonates deeply in a world where, as he and Jeff agree, the true reward of work isn’t what you get from it, but who you become by it. To learn more about Michael and his work: https://www.linkedin.com/in/yournextkeynotespeaker/ https://www.ourfutureiskind.com/

In this episode of Conversations Life Science Leaders Aren't Having, Jeff Harmon welcomes Jill Pellegrino, CEO of AutoCruitment, to the show. AutoCruitment specializes in direct-to-patient recruitment for clinical trials, with a focus on creatively solving patient recruitment challenges. Jill, who became CEO in early 2024, shares her passion for leadership, mentoring women, and the joy she finds in helping people unlock their potential. In her role, she focuses on scaling the company while maintaining the innovative and collaborative spirit of a startup, all while ensuring her team prioritizes the patient experience in clinical trials. Jill discusses how AutoCruitment addresses the complex issue of patient recruitment, often seen as an afterthought in clinical trial planning. With a creative approach that merges marketing strategies with clinical requirements, her team works to unlock the power of patients by reaching underserved populations through broad digital campaigns while also ensuring patient qualification to optimize site referrals. Jeff and Jill explore how her leadership style has evolved from a focus on personal performance to one centered on impact, particularly in helping women in leadership roles grow their confidence. Jill emphasizes the importance of thinking creatively in life sciences and putting the patient at the center of clinical trial planning to truly drive innovation. Tune in to hear how Jill’s experience and leadership have shaped AutoCruitment’s approach to solving patient recruitment challenges and how her mission to unlock the power of the patient is driving success in the life sciences. To learn more about Jill and AutoCruitment: https://www.linkedin.com/in/jill-pellegrino-a85a963/ https://www.autocruitment.com/results/

In the first episode of season eight of Conversations Life Science Leaders Aren't Having, host Jeff Harmon welcomes Ira Spector, CEO of SFA Therapeutics, a biotech startup focused on revolutionary treatments for chronic inflammatory diseases. Ira shares his journey into drug development, recounting a pivotal moment in his career when an advisor told him that by working in research, he had the potential to impact millions rather than treating one patient at a time. This conversation dives into Ira’s passion for making a global impact and his mission to address disease progression, not just symptoms. Throughout the episode, Ira provides a fascinating look into his company's innovative approach to using substances from the GI microbiome to develop immunomodulating drugs. He explains the challenges and rewards of working in a startup environment, highlighting the need for quick decision-making, resource efficiency, and a patient-centered focus. Ira also discusses the mindset shift needed in the biotech industry. He advocates for a move away from treating symptoms toward addressing the root causes of diseases, something that he believes is crucial for the future of medicine. The episode wraps up with Ira’s vision for SFA Therapeutics and its potential to ignite a revolution in medicine by returning the body to homeostasis, with results that could change the landscape of how chronic diseases are treated. This episode is a thought-provoking exploration of leadership in biotech and the life sciences, as well as a call to action for innovation in drug development. To learn more about Ira Specter and SFA Therapeutics, listeners are encouraged to visit the company’s website and connect with Ira on LinkedIn.  https://sfatherapeutics.com/ https://www.linkedin.com/in/ira-spector-00414310/

In the latest episode of "Conversations Life Science Leaders Aren't Having Today," host Jeff welcomes Mick Ebeling, the founder and CEO of Not Impossible Labs, an innovation incubator that devises solutions to social issues. Despite not fitting the typical guest profile of CEOs in drug development or biotech, Mick's work in life sciences is profoundly impactful. His projects range from enabling an artist with ALS to create again using ocular recognition technology to providing independence for amputees in Africa through 3D-printed limbs. The conversation highlights one of Not Impossible Labs' significant initiatives, Bento, which addresses food insecurity. Mick shares how his upbringing shielded him from the concept of food insecurity and how the pandemic intensified the need for innovative solutions like Bento. This initiative provides nutritious food access to those in need through a simple text-based system, delivering groceries curated for specific dietary needs directly to people's doors. Mick's fearless approach to tackling absurdities is a recurring theme. He explains that Not Impossible Labs thrives on facing fears head-on and viewing failure as a stepping stone to success. This mindset has led to revolutionary projects like Eye Rider and Bento, both of which have received significant recognition, including Time Magazine's Top Inventions list. Through engaging stories and profound insights, Mick emphasizes the importance of addressing basic human needs to unlock people's potential. He challenges life science leaders to consider how stabilizing fundamental needs like food can transform communities, reduce healthcare costs, and create a more equitable society. This episode is a testament to the power of innovation, empathy, and relentless pursuit of solutions to improve lives. To learn more… www.gobento.com www.notimpossiblelabs.com\

In this episode of "Conversations Life Science Leaders Aren't Having Today," Jeff welcomes Paul Wotton, the executive director of the Biotech Launchpad at Rice University. The Biotech Launchpad is a dynamic accelerator dedicated to translating the university's health and medical technology discoveries, particularly in the bioengineering and cell engineering departments, to commercialize their technologies swiftly to benefit patients worldwide. Paul is passionate about guiding companies at the Launchpad to envision the future impact of their technology and platforms. Paul's story is shaped by his early exposure to the Apollo 11 moon landing. As a young boy, Paul was captivated by the ambition and success of the US space program, which demonstrated the incredible possibilities achievable through innovation, planning, and determination. Throughout the conversation, Paul delves into his career journey, sharing insights on his role in turning platforms into products. He recounts his experiences in various companies, where he learned the importance of strategy and disciplined execution. Paul emphasizes the significance of understanding patient needs and the value of diverse, interdisciplinary teams in fostering innovation. Jeff and Paul discuss the challenges and opportunities in the biotech industry, with Paul advocating for a bold, visionary approach to problem-solving. He encourages life science leaders to engage in conversations with physicians and focus on impactful, patient-centric solutions. If you're passionate about biotech, innovation, and visionary leadership, you won't want to miss this episode. Paul challenges us to think bigger, solve bigger problems and move beyond “me too” strategies. To learn more about Paul and the Rice BioTech LaunchPad… https://biotechlaunchpad.rice.edu/ https://www.linkedin.com/in/paul-w-15246612/

In this episode of "Conversations Life Science Leaders Aren't Having Today," Jeff welcomes Frank Knuettel, the CEO of Chromocell, a company dedicated to developing innovative, non-addictive alternatives for pain treatment. Frank is a "second mountain guy," someone who has transitioned from focusing on external measures of success to prioritizing people, process, and impact. Frank describes his excitement about being involved in the strategic planning at Chromocell, prioritizing projects, and exploring partnerships to maximize their resources. He explains that while his career began in technology, his recent board work in the life sciences led him to this field, particularly motivated by personal experiences with pain and opioid treatments. Jeff and Frank discuss the challenges and opportunities within the life sciences sector, particularly the need for innovative funding and the potential impact of price controls on drug development. Frank advocates for something akin to the CHIPS Act for the life sciences to ensure that valuable scientific research does not go unfunded. Internally at Chromocell, Frank ensures that good ideas receive attention by prioritizing projects and seeking partners to advance those they cannot pursue independently. He emphasizes the importance of having a team that is comfortable with the risks and variability of working in a small, dynamic company. The episode concludes with Frank expressing his concern about the potential loss of good science due to market downturns and stresses the need for ongoing innovation in pain management. For more information about Chromocell and to stay updated on their progress, listeners are encouraged to visit their website at www.chromocell.com and sign up for their news feeds.

In the latest episode of "Conversations Life Science Leaders Aren't Having Today," Jeff welcomes Leslie Loveless, CEO of Slone Partners, an executive search firm specializing in life sciences and healthcare leadership. Leslie discusses the evolution of Slone Partners, from its inception to its current state with 70 employees, and the importance of culture in their work. She shares the unique approach of implementing an employee-driven culture, which fosters ownership and commitment across the company. Throughout the conversation, Leslie reflects on her journey as a leader, emphasizing the importance of emotional intelligence, patience, and continuous improvement. She candidly discusses the challenges of balancing a commitment to excellence with the need for empathy and understanding. A significant portion of the discussion centers on diversity in the workplace. Leslie shares a personal story about her daughter's experience with diversity and how it has fueled her passion for creating inclusive environments. Leslie emphasizes that addressing diversity requires a strategic approach rather than a quick fix, and she encourages companies to integrate diversity into their core business strategies. This episode is packed with wisdom on achieving excellence through culture, diversity, and leadership, making it a must-listen for anyone looking to create a transformative impact in their organization. To learn more about Leslie or Slone Partners… https://www.linkedin.com/in/leslieloveless1/ https://www.slonepartners.com/

In this episode of "Conversations Life Science Leaders Aren't Having," host Jeff welcomes Nigel McCracken, COO of Virax BioLabs, which focuses on diagnostics for chronic inflammation and T-cell exhaustion. Nigel's career spans 30 years in drug development, with significant contributions to infectious disease and oncology. Recently, his focus has shifted to diagnostics, particularly for post-viral syndromes like long COVID and chronic fatigue syndrome, emphasizing the critical role of early diagnosis in disease management. Nigel's journey reflects a blend of scientific rigor and a profound sense of personal drive, shaped early by his passion for rugby. He discusses how the resilience and team-oriented mentality fostered on the rugby field have influenced his leadership and work ethic in the biotech industry. He highlights the importance of emotional intelligence and team dynamics in leading effectively, acknowledging the need to adapt his leadership style to accommodate diverse team members' needs. As Nigel looks to the future, he's driven by the potential of diagnostics to transform patient care by enabling early intervention. He encourages personal responsibility in health management, suggesting that lifestyle changes could preemptively address conditions like chronic inflammation. His vision for Virax BioLabs includes developing innovative diagnostics that align with personalized medicine, ultimately improving quality of life and managing healthcare sustainability. To learn more about Nigel and Virax BioLabs… https://www.linkedin.com/in/nigel-mccracken-9834677/ https://www.viraxbiolabs.com/